TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has provided an announcement.
Clarity Pharmaceuticals has issued 95,622 fully paid ordinary shares following the exercise of options, without disclosure to investors under the Corporations Act. This move aligns with regulatory compliance and reflects the company’s operational transparency, potentially impacting its market position by enhancing shareholder value.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company specializing in the development of innovative radiopharmaceuticals. The company focuses on targeted copper theranostics using its SAR Technology Platform to treat cancer in both children and adults.
Average Trading Volume: 2,959,118
Technical Sentiment Signal: Buy
Current Market Cap: A$1.69B
For an in-depth examination of CU6 stock, go to TipRanks’ Overview page.